Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis
Diabetes, Obesity and Metabolism · 03.11.2026
DOI: 10.1111/dom.71497 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.11.2026. Verfasst von Abdulkareem Jomaa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Compensated MASH cirrhosis is an advanced disease with no current approved pharmacologic therapy. FGF analogues have shown biological activity, but individual trials have not established histologic efficacy. We aim to evaluate their effects across histologic and non‐invasive outcomes in this population.
Methods
PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched from inception through 8 July 2026 for RCTs comparing FGF analogues with placebo in adults with compensated (F4) MASH cirrhosis. The primary outcome was at least 1‐stage fibrosis improvement without MASH worsening. Secondary outcomes included Pro‐C3, Enhanced Liver Fibrosis (ELF) score and liver stiffness. MASH resolution and safety were exploratory. Random‐effects meta‐analyses were performed. RoB 2 and GRADE assessments were conducted.
Results
Five RCTs involving 589 participants were included. FGF analogues did not significantly improve fibrosis by at least one stage without worsening of MASH (RR, 1.32; 95% CI, 0.89–1.97). In post hoc exploratory analyses, FGF21 analogues increased MASH resolution alone (RR, 3.17; 95% CI, 1.49–6.73), whereas resolution without worsening of fibrosis remained inconclusive (RR, 1.75; 95% CI, 0.95–3.23). Treatment reduced ELF score (MD, −0.52; 95% CI, −0.79 to −0.25), Pro‐C3 (MD, −26.49 percentage points; 95% CI, −40.47 to −12.51) and liver stiffness (MD, −2.30 kPa; 95% CI, −3.90 to −0.71). Serious adverse events were not significantly increased, but adverse‐event‐related discontinuation was more frequent (RR, 3.44; 95% CI, 1.13–10.43). FGF19 findings derive from a single trial (aldafermin).
Conclusions
FGF analogues did not significantly improve the primary fibrosis endpoint, but improved MASH resolution and non‐invasive fibrosis measures, supporting continued evaluation of FGF analogues in Phase 3 trials with longer follow‐up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq.
- Department of Internal Medicine, Midwestern University, Glendale, Arizona, USA.
- Department of Internal Medicine, Willis-Knighton Health System, Shreveport, Louisiana, USA.
- College of Medicine, University of Zakho, Zakho Independent Administration, Kurdistan Region, Iraq.
- Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Gastroenterology and Hepatology, University of Toledo, Toledo, Ohio, USA.
ORCID-Profile: Abdulkareem Jomaa, Rafil Bshara
Zitieren
APA
Jomaa, A., Alani, M., Ismail, B., Hayder, D., Bshara, R., Bshara, R., Jomaa, W., Al-Ibraheem, A., Al-Obaidi, H., & Samant, H. (2026). Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71497
Vancouver
Jomaa A, Alani M, Ismail B, Hayder D, Bshara R, Bshara R, et al. Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71497
BibTeX
@article{Jomaa2026,
author = {Jomaa, Abdulkareem and Alani, Mohammed and Ismail, Bilind and Hayder, Dani and Bshara, Rani and Bshara, Rafil and Jomaa, Wasim and Al-Ibraheem, Abdullah and Al-Obaidi, Hasan and Samant, Hrishikesh},
title = {Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71497}
}
EUVIMED